<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314807</url>
  </required_header>
  <id_info>
    <org_study_id>The Rainbow study</org_study_id>
    <nct_id>NCT01314807</nct_id>
  </id_info>
  <brief_title>Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!</brief_title>
  <official_title>Systemic Consequences and Comorbidities in Mild/Moderate COPD, Time for Action!</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective case-control study is to investigate the prevalence, severity and&#xD;
      incidence of systemic consequences in newly detected patients with mild and moderate Chronic&#xD;
      obstructive pulmonary disease (COPD). Special attention will be paid to skeletal muscle&#xD;
      dysfunction and physical inactivity as these factors are, together with smoking, potentially&#xD;
      modifiable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups will be included in this study:&#xD;
&#xD;
        -  Patients with COPD (cases)&#xD;
&#xD;
        -  Patients with smoking history but no COPD (smoking controls)&#xD;
&#xD;
        -  Patients with no smoking history and no COPD (non-smoking controls)&#xD;
&#xD;
      An extensive test battery will be performed at baseline and after 3 years:&#xD;
&#xD;
      Clinical assessment (height, weight and blood pressure)*&#xD;
&#xD;
      Complete pulmonary function ((post-bronchodilator)spirometry + diffusion)*&#xD;
&#xD;
      Sputum Induction&#xD;
&#xD;
      Fasting venous blood sample (fasting glucose, cholesterol, triglycerides, inflammatory&#xD;
      markers, creatinine, NT pro BNP, hemoglobin, testosterone, vitamin D)&#xD;
&#xD;
      Vascular screening (arterial stiffness - arterial stenosis - CIMT)&#xD;
&#xD;
      Muscle force (peripheral + respiratory)*&#xD;
&#xD;
      Functional exercise capacity (6 MWT)**&#xD;
&#xD;
      Maximal exercise capacity (incremental cycle test)**&#xD;
&#xD;
      Dexa scan (osteoporosis - body composition)&#xD;
&#xD;
      Spiral CT scan of the chest&#xD;
&#xD;
      RX thorax - RX lumbar&#xD;
&#xD;
      Questionnaires (MRC, CCQ, SF-36, EQ5D, HADS, Exacerbation, CATZ)**&#xD;
&#xD;
      Physical activity monitoring (sensewear armband)*&#xD;
&#xD;
      * test will be repeated every 6 months&#xD;
&#xD;
      ** test will be repeated every year&#xD;
&#xD;
      !!!! Remark (26/9/2013) Based on the last data analyses, in contrast to our expectations, we&#xD;
      concluded that the two groups with a smoking history, with or without COPD change in a&#xD;
      similar way over time. The length of the study will therefore be prolonged with 3 more years&#xD;
      (6 years in total).&#xD;
&#xD;
      After 3 years the patients with a smoking history will be evaluated yearly, unless they were&#xD;
      hospitalized for &gt;5 days. In that case we will sooner contact these patients in order to pick&#xD;
      up comorbidities in these patients.!!!&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of risk factors to develop comorbidities (vascular dysfunction, osteoporosis, muscle wasting and metabolic syndrome)</measure>
    <time_frame>baseline</time_frame>
    <description>Common risk factors: smoking, COPD, physical inactivity (steps (per day)and moderate intense PA (min/day) and systemic inflammation (CRP, fibrinogen, IL-6, IL-8, TNF-alpha). Specific risk factors: vascular (atherosclerosis (mean IMT carotid arteries), arterial stenosis (ankle brachial index) and arterial stiffness (brachial ankle pulse wave velocity)), bone (osteopenia: T-score &lt; -1 at lumbar spine/femoral neck/total femur), muscle (fat free mass index &lt; 15/16(female/male) and respiratory/peripheral muscle weakness; &lt; 80%predicted), metabolic (syndrome): definition by AHA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and worsening of risk factors to develop comorbidities (vascular dysfunction, osteoporosis, muscle wasting and metabolic syndrome)</measure>
    <time_frame>3 years</time_frame>
    <description>Common risk factors: smoking, COPD, physical inactivity (steps (per day)and moderate intense PA (min/day) and systemic inflammation (CRP, fibrinogen, IL-6, IL-8, TNF-alpha). Specific risk factors: vascular (atherosclerosis (mean IMT carotid arteries), arterial stenosis (ankle brachial index) and arterial stiffness (brachial ankle pulse wave velocity)), bone (osteopenia: T-score &lt; -1 at lumbar spine/femoral neck/total femur), muscle (fat free mass index &lt; 15/16 (female/male) and respiratory/peripheral muscle weakness; &lt; 80%predicted), metabolic (syndrome): definition by AHA</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>patients with COPD</arm_group_label>
    <description>patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>smoking controls</arm_group_label>
    <description>patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-smoking controls</arm_group_label>
    <description>patients with &lt; 1 pack year who have no COPD (based on post-bronchodilator spirometry)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, cholesterol, LDL, HDL, creatinine, fibrinogen, glucose, insuline, NTproBNP, CRP,&#xD;
      Hba1C&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population-based sample from the general population: random selected patients from the&#xD;
        environment of Leuven (Nelson Study), and co-workers from the University Hospital of Leuven&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 40-80 years old&#xD;
&#xD;
        cases: spirometry (post-bronchodilator) based diagnosis of COPD (GOLD criteria) + smoking&#xD;
        history of at least 10 pack-years and active smoking behavior till at least 10 years from&#xD;
        the moment of enrollment.&#xD;
&#xD;
        smoking controls: no COPD (spirometry based) + smoking history of at least 10 pack-years&#xD;
        and active smoking behavior till at least 10 years from the moment of enrollment.&#xD;
&#xD;
        non-smoking controls: no COPD (spirometry based) + &lt; 1 pack year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Respiratory disorder other than COPD&#xD;
&#xD;
          -  Î±1-antitrypsin deficiency&#xD;
&#xD;
          -  Known history of significant inflammatory disease other than COPD&#xD;
&#xD;
          -  COPD exacerbation within 4 weeks prior to study&#xD;
&#xD;
          -  Lung surgery&#xD;
&#xD;
          -  Recent diagnosis of cancer&#xD;
&#xD;
          -  Therapy with oral corticosteroids in the last 6 weeks&#xD;
&#xD;
          -  Significant cardiovascular comorbidity&#xD;
&#xD;
          -  Significant orthopedic/musculoskeletal problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Troosters, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Thierry Troosters</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

